FDA Approves VIGABATRIN — Zydus Pharmaceuticals (USA) Inc.

# FDA Approves Generic Vigabatrin The FDA has approved Zydus Pharmaceuticals' generic version of vigabatrin, an oral antiepileptic medication, potentially expanding market competition and reducing treatment costs for patients with seizure disorders. The approval of the abbreviated new drug application (ANDA 215707) allows Zydus to enter the vigabatrin market, which could pressure pricing for the branded formulation and increase accessibility for healthcare providers and patients.